- Home
- NML vs ALLO Comparison
NML vs ALLO Comparison
Compare NML & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- ALLO
- Stock Information
- Founded
- NML 2012
- ALLO 2017
- Country
- NML United States
- ALLO United States
- Employees
- NML N/A
- ALLO N/A
- Industry
- NML Finance/Investors Services
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NML Finance
- ALLO Health Care
- Exchange
- NML Nasdaq
- ALLO Nasdaq
- Market Cap
- NML 517.3M
- ALLO 427.7M
- IPO Year
- NML N/A
- ALLO 2018
- Fundamental
- Price
- NML $9.11
- ALLO $2.17
- Analyst Decision
- NML
- ALLO Strong Buy
- Analyst Count
- NML 0
- ALLO 10
- Target Price
- NML N/A
- ALLO $10.06
- AVG Volume (30 Days)
- NML 219.3K
- ALLO 9.8M
- Earning Date
- NML 01-01-0001
- ALLO 03-13-2025
- Dividend Yield
- NML 9.75%
- ALLO N/A
- EPS Growth
- NML N/A
- ALLO N/A
- EPS
- NML N/A
- ALLO N/A
- Revenue
- NML N/A
- ALLO $43,000.00
- Revenue This Year
- NML N/A
- ALLO N/A
- Revenue Next Year
- NML N/A
- ALLO N/A
- P/E Ratio
- NML N/A
- ALLO N/A
- Revenue Growth
- NML N/A
- ALLO 26.47
- 52 Week Low
- NML $6.09
- ALLO $1.32
- 52 Week High
- NML $7.33
- ALLO $5.78
- Technical
- Relative Strength Index (RSI)
- NML 50.49
- ALLO 55.14
- Support Level
- NML $9.01
- ALLO $1.32
- Resistance Level
- NML $9.25
- ALLO $3.78
- Average True Range (ATR)
- NML 0.14
- ALLO 0.36
- MACD
- NML -0.01
- ALLO 0.10
- Stochastic Oscillator
- NML 38.46
- ALLO 34.55
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.